Background: This systemic analysis was conducted to evaluate tumor recurrence rate and one-year survivalrate for patients with liver metastases received radiofrequency ablation after transarterial chemoembolizationand introduce a new method of radiofrequency ablation by puncture navigation technology for single livermetastases after transarterial chemoembolization. Materials and
Methods: Clinical studies evaluating tumorrecurrence rate and one-year survival rate. Appling the innova trackvision software to process one liver metastasesreceived transarterial chemoembolization and using radiofrequency ablation by puncture navigation technologyto treat the liver metastases.
Results: 3 clinical studies which including 235 patients with liver metastasesafter transaeterial chemoembolization were considered eligible for inclusion. Systemic analysis suggested thattumor recurrence rate was 23% (54/235), one-year survival rate was 76% (178/235). The new procedure wasperformed successfully and the patient received a good prognosis.
Conclusions: This systemic analysis suggeststhat radiofrequency ablation is a good method for liver metastases after transarterial chemoembolization andcould receive a relatively good prognosis.